Tempus AI Surges 10.1% on FDA Momentum and AI-Driven Healthcare Breakthroughs

Summary
• Tempus AI (TEM) hits 52-week high of $102.93 amid a 10.1% intraday rally
• FDA clearances for xR IVD and cardiac imaging tools drive institutional buying
• Options chain sees 41.06% leverage ratio on $100 call options as volatility spikes to 83.92%

Tempus AI’s stock has erupted to a record intraday high of $102.40, surging 10.1% from its open of $93.23. This explosive move follows a cascade of FDA clearances for its AI-powered diagnostic tools and a $81M acquisition of digital pathology firm Paige. With turnover hitting 10.5M shares and a 10.9% turnover rate, the stock is now trading near its 52-week peak as institutional buyers and retail traders alike chase the momentum.

FDA Clearances and AI Innovations Fuel Tempus AI's Record High
The surge is directly tied to Tempus AI’s recent regulatory wins and strategic acquisitions. The company secured FDA clearance for its Tempus xR IVD device, enhancing drug discovery capabilities, and updated Pixel cardiac imaging platform. These approvals validate its AI-driven approach to precision medicine. Additionally, the $81M acquisition of Paige—a leader in digital pathology—positions Tempus to accelerate AI model development for cancer diagnostics. Institutional buying pressure is evident in the options chain, where the $100 call option (TEM20251017C100) has seen 4.6M in turnover and a 194.24% price change ratio, reflecting aggressive bullish positioning.

Healthcare Equipment Sector Gains Momentum as Tempus AI Outpaces Peers
The Health Care Equipment and Supplies sector is seeing renewed interest as the Trump administration initiates a Section 232 probe into medical device imports, potentially paving the way for tariffs on surgical masks, glucose monitors, and hospital equipment. Sector leader Illumina (ILMN) is up 1.06% on the day, but Tempus AI’s 10.1% rally dwarfs its peers. The sector’s focus on AI integration and regulatory tailwinds—exemplified by Tempus’s FDA clearances—highlights a shift toward technology-driven medical solutions.

High-Leverage Call Options and ETFs Capitalize on Tempus AI’s Bullish Momentum
• MACD: 3.72 (above signal line 3.08), RSI: 61.50 (neutral), Bollinger Bands: Price at 95.37 (upper) vs. 85.33 (middle)
• 200-day average: $60.21 (well below current price), Support/Resistance: 77.99–78.39 (30D), 57.56–58.78 (200D)

Tempus AI’s technicals confirm a strong short-term bullish trend. The stock is trading above all major moving averages and within a 10% range of its 52-week high. For options traders, the TEM20251017C100 call option (strike $100, expiration 10/17) stands out with 14.46% leverage ratio and 83.92% implied volatility. Its 194.24% price change ratio and 2.1M turnover indicate high liquidity. A 5% upside to $107.52 would yield a payoff of $7.52 per contract. The TEM20251017C95 call (strike $95) also offers 10.06% leverage and 83.88% IV, with 143.90% price change ratio. Both contracts benefit from high gamma (0.027) and theta (-0.50), making them ideal for short-term volatility plays. Aggressive bulls should target a $105 breakout, with stop-loss near the 91.87 intraday low.

Backtest Tempus AI Stock Performance
Below is the event-study back-test of “Tempus AI (TEM.O)” after each intraday price surge of at least +10 % (High vs. previous Close) since 1 Jan 2022.Key take-aways1. Event frequency: 30 occurrences over the sample period.2. The average performance after a +10 % intraday spike is consistently negative; by day 5 the cumulative event return is -6 % vs. the benchmark’s +2.9 %.3. Drawdown persists out to 30 trading days (-8.9 % cumulative vs. benchmark +14.4 %), with statistical significance at each horizon.Assumptions & methodology• Surge definition: (High – Prev-Close) / Prev-Close ≥ 10 %. • Entry at next day’s open, exit after N days (1-30) – transaction costs ignored. • Data source: TEM daily OHLC, 1 Jan 2022 – 8 Oct 2025.You can explore all horizons and additional statistics in the interactive module above.

Tempus AI’s Bullish Momentum: Key Levels and Strategic Entry Points
Tempus AI’s 10.1% surge is driven by a perfect storm of FDA validations, AI-driven acquisitions, and sector-wide regulatory tailwinds. The stock’s proximity to its 52-week high and strong options liquidity suggest the rally could extend. Sector leader Illumina’s 1.06% gain underscores broader healthcare equipment optimism. Investors should monitor the $100 psychological level and the 95.37 Bollinger upper band. If $105 breaks, the TEM20251017C100 call option offers high leverage for a potential 7.52% payoff. Watch for follow-through volume and a sustained close above $102.93 to confirm the breakout.